RhoC, a GTPase oncogene, regulates cytoskeleton organization and various cellular functions (such as cell motility, cell polarity, and cell division). Increased expression of RhoC correlates to a poor prognosis in several cancers, including pancreatic ductal carcinoma, breast cancer, skin cancer, ovarian cancer, liver cancer, and head & neck cancer (Thomas et. al, 2019).
Because of RhoC’s roles as an oncogene, it is a promising target in drug discovery. MicroRNAs (miRNAs) are examples of already established RhoC expression regulators (Thomas et. al, 2019). The Transcreener GDP RhoC Assay is an excellent tool for researchers examining RhoC for therapeutic treatments.